MARKET

NVRO

NVRO

Nevro Corp
NYSE

Real-time Quotes | Nasdaq Last Sale

44.72
+0.28
+0.63%
After Hours: 44.72 0 0.00% 16:00 05/20 EDT
OPEN
45.55
PREV CLOSE
44.44
HIGH
45.89
LOW
42.81
VOLUME
642.02K
TURNOVER
0
52 WEEK HIGH
182.45
52 WEEK LOW
41.74
MARKET CAP
1.58B
P/E (TTM)
-11.4776
1D
5D
1M
3M
1Y
5Y
Nevro's Return On Capital Employed Overview
Benzinga Pro data, Nevro (NYSE:NVRO) reported Q1 sales of $87.84 million. Earnings fell to a loss of $34.33 million, resulting in a 13.91% decrease from last quarter.
Benzinga · 2d ago
Nevro (NVRO) Stock Falls 19% Despite Q1 Earnings Beat
Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q1 partly due to soft domestic performance.
Zacks · 05/09 15:15
Where Nevro Stands With Analysts
Nevro (NYSE:NVRO) has observed the following analyst ratings within the last quarter:
Benzinga · 05/05 20:37
--Citigroup Upgrades Nevro to Buy From Neutral; Price Target is $78
MT Newswires · 05/05 07:41
--Piper Sandler Adjusts Nevro's Price Target to $64 From $65, Maintains Neutral Rating
MT Newswires · 05/05 07:03
Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates
Nevro (NVRO) delivered earnings and revenue surprises of 11.71% and 2.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 22:25
BRIEF-Nevro Reports First Quarter 2022 Financial Results
reuters.com · 05/04 22:18
Recap: Nevro Q1 Earnings
Nevro (NYSE:NVRO) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Nevro beat estimated earnings by 10.91%, reporting an EPS of $-0.98 versus an estimate of $-1.1.
Benzinga · 05/04 21:56
More
No Data
Learn about the latest financial forecast of NVRO. Analyze the recent business situations of Nevro Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

14.29%Strong Buy
14.29%Buy
57.14%Hold
7.14%Under-perform
7.14%Sell
Analyst Price Target
The average NVRO stock price target is 76.40 with a high estimate of 125.00 and a low estimate of 49.00.
High125.00
Average76.40
Low49.00
Current 44.72
EPS
Actual
Estimate
-1.15-0.86-0.58-0.29
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 288
Institutional Holdings: 43.52M
% Owned: 123.42%
Shares Outstanding: 35.26M
TypeInstitutionsShares
Increased
88
6.19M
New
19
321.31K
Decreased
59
1.38M
Sold Out
32
5.52M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.35%
Healthcare Equipment & Supplies
+0.36%
Key Executives
Chairman/President/Chief Executive Officer/Director
D. Keith Grossman
Chief Financial Officer
Roderick Macleod
Chief Human Resource Officer
Lori Ciano
Vice President
Christopher Christoforou
Vice President
Donald Middlebrook
Vice President
Jon Shear
General Counsel/Secretary
Kashif Rashid
Other
David Caraway
Other
Niamh Pellegrini
Lead Director/Independent Director
Michael DeMane
Independent Director
Frank Fischer
Independent Director
Sridhar Kosaraju
Independent Director
Shawn Mccormick
Independent Director
Kevin O'Boyle
Independent Director
Karen Prange
Independent Director
Susan Siegel
Independent Director
Brad Vale
Independent Director
Elizabeth Weatherman
No Data
No Data
About NVRO
Nevro Corp. is a global medical device company that provides solutions for the treatment of chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain, with the Senza Omnia platform. Its Senza System, Senza II System, and the Senza Omnia System are the SCS systems that delivers Nevro's 10 kilohertz (kHz) therapy. The Senza system is focused on creating traditional low frequency electrical impulses and its HF10 therapy, which allows for pain relief without paresthesia. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. The HF10 therapy delivers waveforms at 10,000 Hertz (Hz) pulse rate with a statistically driven and clinically verified programming algorithm.

Webull offers kinds of Nevro Corp stock information, including NYSE:NVRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVRO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVRO stock methods without spending real money on the virtual paper trading platform.